Give And Take As China Finalizes Biosimilars Guideline
This article was originally published in PharmAsia News
Executive Summary
Three months after publishing a draft guideline on biosimilars, China's Food and Drug Administration (CFDA) has just released the final official version, although it is still dubbed a pilot scheme. The new guideline may superficially look similar to the draft, but a closer comparison reveals some key differences.